Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vaximm GmbH
ClinicalTrials.gov Identifier:
NCT01486329
First received: December 2, 2011
Last updated: June 5, 2015
Last verified: June 2015